Who are Pegylated IFN- alpha 2b's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low-dose anrikefon, Peginterferon Alfa, PEG-Intron + Ribavirin, Peginterferon-α-2a, PEG-IFN-SA /RBV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegylated-ifn-alpha-2b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pegylated IFN- alpha 2b — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegylated IFN- alpha 2b (Pegylated IFN- alpha 2b) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon-alpha. Area: Immunology, Virology, Oncology.

marketed Interferon-alpha Interferon-alpha receptor (IFNAR) Immunology, Virology, Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pegylated IFN- alpha 2b (Pegylated IFN- alpha 2b) — Ain Shams University. Pegylated interferon-alpha 2b activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pegylated IFN- alpha 2b TARGET	Pegylated IFN- alpha 2b	Ain Shams University	marketed	Interferon-alpha	Interferon-alpha receptor (IFNAR)
Low-dose anrikefon	Low-dose anrikefon	Peking University First Hospital	marketed	Interferon-alpha analog	Interferon-alpha receptor (IFNAR)
Peginterferon Alfa	Peginterferon Alfa	Third Affiliated Hospital, Sun Yat-Sen University	marketed	Interferon-alpha	Interferon-alpha receptor (IFNAR)
PEG-Intron + Ribavirin	PEG-Intron + Ribavirin	PharmaEssentia	phase 3	Interferon-alpha and antiviral	Interferon receptors
Peginterferon-α-2a	Peginterferon-α-2a	Ministry of Health, Malaysia	phase 3	Interferon-alpha, pegylated	Interferon-alpha receptor (IFNAR)
PEG-IFN-SA /RBV	PEG-IFN-SA /RBV	Beijing Kawin Technology Share-Holding Co., Ltd.	phase 3	Pegylated interferon-alpha with nucleoside analog	Interferon-alpha receptor; viral RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon-alpha class)

Ain Shams University · 1 drug in this class
Third Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegylated IFN- alpha 2b — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-ifn-alpha-2b. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab